Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
Anticancer immune therapies aim at the induction of tumor-specific T cells, which ultimately should kill tumor cells. The effector cells should, therefore, not only exert cytotoxic activity but also home to and infiltrate the tumor site. Hence, monitoring of immune modulating therapies should not be restricted to the circulating pool of peripheral blood mononuclear cells (PBMC) but also include tumor-infiltrating lymphocytes (TIL), as well as the correlation of these findings to the clinical course. We report here on the longitudinal immunologic workup of a melanoma patient who developed remarkably potent ex vivo detectable antimelanoma cytotoxic T-cell (CTL) responses after vaccinations with autologous peptide-pulsed dendritic cells. Such potent CTL responses to multiple tumor antigens have, to the best of our knowledge, not been described previously in melanoma patients, neither spontaneously nor after any therapy. This patient first experienced a transient response to therapy but finally succumbed to disease progression and died. Progression was associated with the decline of the numbers of tumor-reactive T cells in circulation and at skin metastases in addition to the loss of MHC class I antigens. The immunologic analysis revealed that fully functional tumor-specific T cells were present in the peripheral blood of this patient during the phase of a relatively stable disease, and in situ tetramer staining demonstrated that these cells were also accumulated at cutaneous and visceral tumor sites. Furthermore, comparative clonotype mapping of PBMC and TIL depicted an overlapping TCR repertoire usage among these 2 compartments. Since strong CTL responses as observed in this patient are the goal of cancer vaccination but are so far only rarely observed, the thorough analysis of patients exhibiting either exceptional clinical and/or immunologic responses appears critical to understanding how vaccine therapies work and can be further improved.
Berger
Thomas G
TG
Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany.
Haendle
Ina
I
Schrama
David
D
Lüftl
Matthias
M
Bauer
Nicolas
N
Pedersen
Lars Østergaard
LØ
Schuler-Thurner
Beatrice
B
Hohenberger
Werner
W
Straten Pt
Per thor
Pt
Schuler
Gerold
G
Becker
Jürgen C
JC
D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology; D001483:Base Sequence; D019496:Cancer Vaccines; D003713:Dendritic Cells / Q000276:immunology*; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D018655:Lymphocyte Count; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D008969:Molecular Sequence Data; D009000:Monocytes / Q000276:immunology; D009362:Neoplasm Metastasis; D009360:Neoplastic Cells, Circulating; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines